333 related articles for article (PubMed ID: 32620919)
1. Evolving insights into the genomic complexity and immune landscape of diffuse large B-cell lymphoma: opportunities for novel biomarkers.
El Hussein S; Shaw KRM; Vega F
Mod Pathol; 2020 Dec; 33(12):2422-2436. PubMed ID: 32620919
[TBL] [Abstract][Full Text] [Related]
2. Immune microenvironment-related gene mapping predicts immunochemotherapy response and prognosis in diffuse large B-cell lymphoma.
Chen W; Liang W; He Y; Liu C; Chen H; Lv P; Yao Y; Zhou H
Med Oncol; 2022 Jan; 39(4):44. PubMed ID: 35092504
[TBL] [Abstract][Full Text] [Related]
3. Toward a New Molecular Taxonomy of Diffuse Large B-cell Lymphoma.
Ennishi D; Hsi ED; Steidl C; Scott DW
Cancer Discov; 2020 Sep; 10(9):1267-1281. PubMed ID: 32616477
[TBL] [Abstract][Full Text] [Related]
4. A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications.
Wright GW; Huang DW; Phelan JD; Coulibaly ZA; Roulland S; Young RM; Wang JQ; Schmitz R; Morin RD; Tang J; Jiang A; Bagaev A; Plotnikova O; Kotlov N; Johnson CA; Wilson WH; Scott DW; Staudt LM
Cancer Cell; 2020 Apr; 37(4):551-568.e14. PubMed ID: 32289277
[TBL] [Abstract][Full Text] [Related]
5. Diffuse large B-cell lymphoma.
Li S; Young KH; Medeiros LJ
Pathology; 2018 Jan; 50(1):74-87. PubMed ID: 29167021
[TBL] [Abstract][Full Text] [Related]
6. Intra-tumour heterogeneity of diffuse large B-cell lymphoma involves the induction of diversified stroma-tumour interfaces.
Sangaletti S; Iannelli F; Zanardi F; Cancila V; Portararo P; Botti L; Vacca D; Chiodoni C; Di Napoli A; Valenti C; Rizzello C; Vegliante MC; Pisati F; Gulino A; Ponzoni M; Colombo MP; Tripodo C
EBioMedicine; 2020 Nov; 61():103055. PubMed ID: 33096480
[TBL] [Abstract][Full Text] [Related]
7. Molecular complexity of diffuse large B-cell lymphoma: a molecular perspective and therapeutic implications.
Almasmoum HA
J Appl Genet; 2024 Feb; 65(1):57-72. PubMed ID: 38001281
[TBL] [Abstract][Full Text] [Related]
8. Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma.
You H; Xu-Monette ZY; Wei L; Nunns H; Nagy ML; Bhagat G; Fang X; Zhu F; Visco C; Tzankov A; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; Hagemeister FB; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Van Krieken JH; Piris MA; Winter JN; Li Y; Au Q; Xu B; Albitar M; Young KH
Oncoimmunology; 2021; 10(1):1928365. PubMed ID: 34350060
[TBL] [Abstract][Full Text] [Related]
9. Molecular heterogeneity in diffuse large B-cell lymphoma and its implications in clinical diagnosis and treatment.
Guo L; Lin P; Xiong H; Tu S; Chen G
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):85-96. PubMed ID: 29337112
[TBL] [Abstract][Full Text] [Related]
10. Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma: Genetic Classification and Its Implications for Prognosis and Treatment.
Crombie JL; Armand P
Hematol Oncol Clin North Am; 2019 Aug; 33(4):575-585. PubMed ID: 31229155
[TBL] [Abstract][Full Text] [Related]
11. Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era.
Bohers E; Mareschal S; Bertrand P; Viailly PJ; Dubois S; Maingonnat C; Ruminy P; Tilly H; Jardin F
Leuk Lymphoma; 2015 May; 56(5):1213-22. PubMed ID: 25130477
[TBL] [Abstract][Full Text] [Related]
12. International Prognostic Index-Based Immune Prognostic Model for Diffuse Large B-Cell Lymphoma.
Mu S; Shi D; Ai L; Fan F; Peng F; Sun C; Hu Y
Front Immunol; 2021; 12():732006. PubMed ID: 34745101
[TBL] [Abstract][Full Text] [Related]
13. Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing.
Morin RD; Mungall K; Pleasance E; Mungall AJ; Goya R; Huff RD; Scott DW; Ding J; Roth A; Chiu R; Corbett RD; Chan FC; Mendez-Lago M; Trinh DL; Bolger-Munro M; Taylor G; Hadj Khodabakhshi A; Ben-Neriah S; Pon J; Meissner B; Woolcock B; Farnoud N; Rogic S; Lim EL; Johnson NA; Shah S; Jones S; Steidl C; Holt R; Birol I; Moore R; Connors JM; Gascoyne RD; Marra MA
Blood; 2013 Aug; 122(7):1256-65. PubMed ID: 23699601
[TBL] [Abstract][Full Text] [Related]
14. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma.
Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J
Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885
[TBL] [Abstract][Full Text] [Related]
15. Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.
Chapuy B; Cheng H; Watahiki A; Ducar MD; Tan Y; Chen L; Roemer MG; Ouyang J; Christie AL; Zhang L; Gusenleitner D; Abo RP; Farinha P; von Bonin F; Thorner AR; Sun HH; Gascoyne RD; Pinkus GS; van Hummelen P; Wulf GG; Aster JC; Weinstock DM; Monti S; Rodig SJ; Wang Y; Shipp MA
Blood; 2016 May; 127(18):2203-13. PubMed ID: 26773040
[TBL] [Abstract][Full Text] [Related]
16. Beyond genomics - Targeting the epigenome in diffuse large B-cell lymphoma.
Kühnl A; Cunningham D; Chau I
Cancer Treat Rev; 2017 Sep; 59():132-137. PubMed ID: 28822237
[TBL] [Abstract][Full Text] [Related]
17. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
Camicia R; Winkler HC; Hassa PO
Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
[TBL] [Abstract][Full Text] [Related]
18. An Immune-Related Prognostic Classifier Is Associated with Diffuse Large B Cell Lymphoma Microenvironment.
Liang XJ; Fu RY; Wang HN; Yang J; Yao N; Liu XD; Wang L
J Immunol Res; 2021; 2021():5564568. PubMed ID: 34212052
[TBL] [Abstract][Full Text] [Related]
19. Evidence-based review of genomic aberrations in diffuse large B cell lymphoma, not otherwise specified (DLBCL, NOS): Report from the cancer genomics consortium lymphoma working group.
Yenamandra AK; Smith RB; Senaratne TN; Kang SL; Fink JM; Corboy G; Hodge CA; Lu X; Mathew S; Crocker S; Fang M
Cancer Genet; 2022 Nov; 268-269():1-21. PubMed ID: 35970109
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL).
Isshiki Y; Melnick A
Curr Cancer Drug Targets; 2021; 21(4):274-282. PubMed ID: 33413063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
